Last reviewed · How we verify
The TR group
The TR group, marketed by Beijing Tiantan Hospital, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | The TR group |
|---|---|
| Sponsor | Beijing Tiantan Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SUBDIMA: Subclinical Depression in Acute Myocardial Infarction (SUBDIMA25) (NA)
- ECG Findings in Methamphetamine Use
- Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer (PHASE1)
- LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis
- LRFN5 and OLFM4 in Schizoaffective Disorder
- IL-33, sST2, and CRP in Panic Disorder
- Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial (NA)
- Telerehabilitation In The Home After Stroke (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- The TR group CI brief — competitive landscape report
- The TR group updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI